Skip to main content
TipRanks
Go Ultimate75% OFF

Mineralys Therapeutics, Inc. (MLYS) Drug Pipeline

614 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
LorundrostatHypertension, Obstructive Sleep ApneaPhase IIActive Not RecruitingA Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionJan 16, 2025―
Lorundrostat Dose 1, Lorundrostat Dose 2HypertensionPhase IIICompletedEfficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNov 17, 2023―
LorundrostatHypertensionPhase IIIActive Not RecruitingOpen-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionJul 14, 2023―
Lorundrostat Dose 1, Lorundrostat Dose 2HypertensionPhase IICompletedA Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenFeb 24, 2023―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mineralys Therapeutics, Inc. (MLYS) have in its pipeline
Mineralys Therapeutics, Inc. MLYS is currently developing the following drugs: Lorundrostat, Lorundrostat Dose 1, Lorundrostat Dose 2. These drug candidates are in various stages of clinical development as the company works toward FDA approval.